multiplex protein diagnostics

Using a protein biomarker signature, the company is advancing a CHK1/2 inhibitor that Eli Lilly out-licensed after seeing limited responses in genomic subgroups.

Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.

Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.